Revenue increased 37.3%
Revenue changed +37.3% from the comparable as-filed period.
$533.4M→$732.5M3 prior comparisons
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Revenue changed +37.3% from the comparable as-filed period.
Cash & equivalents changed +137.9% from the comparable as-filed period.
Capex / revenue changed +503 basis points from the comparable as-filed period.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.